Dialysate magnesium - a novel tool to abrogate dialysis-induced myocardial stunning?

Not Applicable

Completed

• Conditions: Dialysis-induced myocardial stunning; Surgery; Myocardial stunning

• Registration Number: ISRCTN37809057
• Lead Sponsor: Derby Hospitals NHS Foundation Trust (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2010-11-04
• Last Update Posted: 17 October 2016

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

1. Over 18 years old, either sex
2. Chronic haemodialysis greater than 3 months

Exclusion Criteria

1. New York Heart Association (NYHA) grade IV heart failure
2. Cardiac transplant
3. Known disorder of magnesium metabolism
4. Magnesium supplementation
5. Recent arrhythmia

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Development of regional wall motion abnormalities. <br>Key observations are taken pre-dialysis (baseline), 15 minutes prior to end of dialysis (peak stress) by cardiac echocardiography (for later offline semi-automated analysis for regional wall motion abnormalities).

Secondary Outcome Measures

Name	Time	Method
Haemodynamic variables observed pre-dialysis, and throughout dialysis treatment, with continuous non-invasive measurement by finometer, and NICOM (bioreactance).